MPS Pharmaa Limited has published its unaudited financial results for the third quarter and nine months ended December 31, 2025, revealing continued operational challenges with widening losses across all reporting periods.

Financial Performance Overview

The pharmaceutical company reported deteriorating financial performance across key metrics for Q3FY26. The company's financial results demonstrate persistent operational difficulties with no revenue generation from core business activities.

Earnings Per Share Analysis

The company's earnings per share metrics reflected the ongoing losses, with both basic and diluted EPS remaining in negative territory. For the quarter ended December 31, 2025, both basic and diluted EPS stood at negative ₹0.12, compared to negative ₹0.09 in the corresponding quarter of the previous year.

For the nine-month period, the EPS deteriorated further to negative ₹0.35 for both basic and diluted calculations, indicating the cumulative impact of sustained losses on shareholder value.

Capital Structure

The company maintained its equity share capital at ₹1,911.14 lakh throughout the reporting periods, with no changes in the capital structure. The face value of equity shares remains at ₹10 each.

Operational Challenges

A significant concern highlighted in the results is the complete absence of operational income during both the current quarter and nine-month period ended December 31, 2025. This contrasts with the previous year's Q3FY25, when the company recorded operational income of ₹4.38 lakh.

Regulatory Compliance

MPS Pharmaa Limited, formerly known as Advvik Laboratories Limited, submitted the financial results in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published the results in Financial Express (English) and Jansatta (Hindi) newspapers on February 3, 2026.

The complete financial results are available on stock exchange websites including BSE ( www.bseindia.com ) and ASE ( www.aselindia.co.in ), as well as on the company's website www.mpspharmaa.com . The results were signed by Chairman Peevush Kumar Aggarwal (DIN: 00090423) on February 2, 2026.

MPS Limited announced its Q3FY26 financial results for the quarter ended December 31, 2025, showing consolidated revenue growth of 20% year-over-year. The Board of Directors, in their meeting held on February 02, 2026, approved the unaudited financial results and addressed several key corporate matters including a director resignation.

Q3FY26 Financial Performance

The company's consolidated financial results demonstrate mixed performance with revenue growth offset by margin pressures:

On a standalone basis, the company reported revenue from operations of ₹1,081.20 crores for Q3FY26 compared to ₹900.90 crores in the corresponding quarter of the previous year, representing a growth of 20.01%.

Segment-wise Performance

The company's business segments showed varied performance during the quarter:

Board Meeting Outcomes

The Board of Directors addressed several important matters during their meeting:

Exceptional Items Impact

The company reported exceptional items of ₹73.80 crores (net) for Q3FY26, primarily related to the implementation of new Labour Codes notified by the Government of India on November 21, 2025. The incremental impact consisted of gratuity provisions of ₹52.40 crores and long-term compensated absences of ₹17.80 crores.

Corporate Developments

Ms. Yamini Tandon resigned from her position as Non-Executive Director with effect from February 02, 2026, due to personal reasons. Consequently, she also ceased to be Chairperson of the Stakeholders' Relationship Committee and Member of the Corporate Social Responsibility Committee and Risk Management Committee.

Nine Months Performance

For the nine months ended December 31, 2025, the company reported consolidated revenue of ₹5,632.10 crores compared to ₹5,447.80 crores in the corresponding period of the previous year, representing growth of 3.38%. Consolidated net profit for the nine months period stood at ₹1,261.80 crores compared to ₹1,018.40 crores in the previous year.